In the last annual meeting of the American Society for Clinical Oncology (ASCO), several randomized studies were presented which investigated the activity of cetuximab-based combination therapy as first line treatment, in dependence on the status – New Small-Molecule Inhibitors Neurodegeneration and Neuropathic Pain

In the last annual meeting of the American Society for Clinical Oncology (ASCO), several randomized studies were presented which investigated the activity of cetuximab-based combination therapy as first line treatment, in dependence on the status. rate only in patients with the wild-type gene. gene are linked to tumor resistance to EGFR inhibitors, as mutations lead … Continue reading In the last annual meeting of the American Society for Clinical Oncology (ASCO), several randomized studies were presented which investigated the activity of cetuximab-based combination therapy as first line treatment, in dependence on the status